Search

Vanda Pharmaceuticals Inc

Lezárt

5.32 1.53

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

5.13

Maximum

5.38

Fő mutatók

By Trading Economics

Bevétel

93M

-49M

Értékesítés

-5.5M

52M

Egy részvényre jutó nyereség

-0.46

Profit margin

-93.907

Munkavállalók

533

EBITDA

-10M

-45M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+256.98% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-140M

315M

Előző nyitás

3.79

Előző zárás

5.32

Vanda Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 4. 23:56 UTC

News

Starbucks Corp raised its full-year EPS guidance to approximately $2.60, reflecting strong U.S. same-store sales growth. Shares are gaining in after-market trading.

2026. aug. 4. 23:56 UTC

News

Alphabet Inc's market valuation is approximately $4.6 trillion, bolstered by strong second-quarter results. Shares traded higher in after-market hours, reflecting positive sentiment.

2026. aug. 4. 23:56 UTC

News

Ameresco Inc reported second-quarter revenue of $515.5 million, a 9% increase year-over-year. Shares are trading higher in after-market hours following the results.

2026. aug. 4. 23:56 UTC

News

Advanced Energy Industries reported record Q2 revenue of $574.1 million, leading to shares trading higher in after-market hours.

2026. aug. 4. 23:51 UTC

News

Cooper-Standard Holdings will present at the J.P. Morgan 2026 Auto Conference on August 12, with a focus on business strategies. Shares traded little changed after hours.

2026. aug. 4. 23:51 UTC

News

Teradata Corp shares fell in after-market hours following mixed Q2 results and disappointing Q3 guidance, projecting adjusted EPS of $0.55 to $0.59.

2026. aug. 4. 23:51 UTC

News

8x8 Inc. shares are lower in after-market hours following mixed first-quarter results, with revenue exceeding expectations but second-quarter EPS guidance falling short.

2026. aug. 4. 23:51 UTC

News

Hyster-Yale Materials Handling shares fell in after-market trading following a second-quarter revenue of $812.9 million and a net loss of $31.6 million.

2026. aug. 4. 23:51 UTC

Social Media
News

Arista Networks shares higher in after-market hours following strong second-quarter results, with adjusted EPS of $1.02 and optimistic third-quarter guidance.

2026. aug. 4. 23:51 UTC

News
Social Media

Hecla Mining Co reported second-quarter EPS of $0.17 and revenue of $333.85 million, exceeding expectations. Shares are higher in after-market trading.

2026. aug. 4. 23:51 UTC

Correlated Moves
ETF Constituents
News
Macro News

Vanguard Information Technology ETF is trading higher in after-market hours, supported by strong earnings from tech stocks and positive sentiment from UBS's coupon payments.

2026. aug. 4. 23:46 UTC

News

Teladoc Health faces scrutiny amid revenue miss and lowered outlook. Shares traded roughly flat in after-market hours following the developments.

2026. aug. 4. 23:42 UTC

News

Apple Inc. seeks a preliminary injunction against OpenAI amid a legal battle, as shares trade higher in after-market hours.

2026. aug. 4. 23:41 UTC

News

Shutterstock shares are higher in after-market hours despite a $155.9 million net loss and a $173.7 million goodwill impairment charge reported for Q2.

2026. aug. 4. 23:41 UTC

News

Compass Inc. shares rise in after-market hours following strong Q2 revenue of $4.306 billion and optimistic Q3 guidance of $3.85 billion to $4.05 billion.

2026. aug. 4. 23:41 UTC

News
Social Media

Lumen Technologies reported second-quarter revenue of $2.805 billion, exceeding estimates. Shares rose after hours as the company reaffirmed its full-year guidance.

2026. aug. 4. 23:41 UTC

News

Flywire Corp reported strong Q2 results, with revenue surpassing estimates. Shares are higher in after-market trading following the raised full-year guidance.

2026. aug. 4. 23:41 UTC

News

Community Healthcare Trust shares declined in after-market hours following second-quarter results that missed earnings and revenue expectations. EPS was $0.06 versus an estimated $0.12.

2026. aug. 4. 23:41 UTC

News

Bruker shares higher in after-market hours following Jefferies' price target increase to $62.00, maintaining a Buy rating amid broader performance challenges.

2026. aug. 4. 23:41 UTC

Social Media
News

Alphabet Inc shares are higher in after-market trading following the expansion of its Gemini feature in Google Classroom for K-12 users.

2026. aug. 4. 23:41 UTC

News
Social Media

Zeta Global Holdings reported Q2 revenue of $443 million but shares fell in after-market trading amid mixed reactions and concerns over growth guidance.

2026. aug. 4. 23:41 UTC

Social Media
News

Palantir Technologies reported strong second-quarter results but shares fell during after-market hours, overshadowed by broader market gains and mixed sentiment.

2026. aug. 4. 23:41 UTC

Social Media
News

Rocket Lab USA Inc secures a $397 million contract from the U.S. Space Force, driving shares higher in after-market trading.

2026. aug. 4. 23:41 UTC

News

IDEXX Laboratories reported second-quarter revenue of $1.22 billion, a 9.7% increase year-over-year. Shares are trading higher in after-market hours following the results.

2026. aug. 4. 23:41 UTC

Social Media
News

Kratos Defense and Security Solutions reported Q2 revenues of $458.8 million, exceeding estimates. Shares are advancing in after-market trading amid raised sales guidance.

2026. aug. 4. 23:36 UTC

News

EOG Resources reported strong Q2 earnings of $5.15 per share and revenues of $8.62 billion, contributing to shares trading higher in after-market hours.

2026. aug. 4. 23:36 UTC

News

Alphatec Holdings shares fell in after-market trading following a net loss of $26 million, despite meeting adjusted EPS expectations and exceeding revenue forecasts.

2026. aug. 4. 23:36 UTC

News

Dell Technologies reported nearly 40% of revenue now from AI initiatives. Shares are lower in after-market trading following the announcement.

2026. aug. 4. 23:36 UTC

News

Marathon Petroleum shares higher in after-market trading, reflecting stable performance and a market capitalization of approximately $91.74 billion.

2026. aug. 4. 23:36 UTC

News

Western Union has launched the Stablecard for international transfers, but shares are trading lower in after-market hours following routine trading activity.

Társak összehasonlítása

Árváltozás

Vanda Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

256.98% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 18.67 USD  256.98%

Magas 21 USD

Alacsony 17 USD

3 Wall Street elemző 12 hónapos célárain alapulva a(z)Vanda Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

3 ratings

3

Vétel

0

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
help-icon Live chat